Copyright Reports & Markets. All rights reserved.

Global Gene Therapy For Heart Failure Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Gene Therapy For Heart Failure
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Gene Therapy For Heart Failure by Type
    • 1.3.1 Overview: Global Gene Therapy For Heart Failure Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Gene Therapy For Heart Failure Consumption Value Market Share by Type in 2022
    • 1.3.3 Gene Modification
    • 1.3.4 Gene Replacement
    • 1.3.5 Others
  • 1.4 Global Gene Therapy For Heart Failure Market by Application
    • 1.4.1 Overview: Global Gene Therapy For Heart Failure Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital
    • 1.4.3 Laboratory
    • 1.4.4 Others
  • 1.5 Global Gene Therapy For Heart Failure Market Size & Forecast
  • 1.6 Global Gene Therapy For Heart Failure Market Size and Forecast by Region
    • 1.6.1 Global Gene Therapy For Heart Failure Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Gene Therapy For Heart Failure Market Size by Region, (2018-2029)
    • 1.6.3 North America Gene Therapy For Heart Failure Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Gene Therapy For Heart Failure Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Gene Therapy For Heart Failure Market Size and Prospect (2018-2029)
    • 1.6.6 South America Gene Therapy For Heart Failure Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Gene Therapy For Heart Failure Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Askbio
    • 2.1.1 Askbio Details
    • 2.1.2 Askbio Major Business
    • 2.1.3 Askbio Gene Therapy For Heart Failure Product and Solutions
    • 2.1.4 Askbio Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Askbio Recent Developments and Future Plans
  • 2.2 RENOVACORINC
    • 2.2.1 RENOVACORINC Details
    • 2.2.2 RENOVACORINC Major Business
    • 2.2.3 RENOVACORINC Gene Therapy For Heart Failure Product and Solutions
    • 2.2.4 RENOVACORINC Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 RENOVACORINC Recent Developments and Future Plans
  • 2.3 Uniqure
    • 2.3.1 Uniqure Details
    • 2.3.2 Uniqure Major Business
    • 2.3.3 Uniqure Gene Therapy For Heart Failure Product and Solutions
    • 2.3.4 Uniqure Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Uniqure Recent Developments and Future Plans
  • 2.4 DINAQOR
    • 2.4.1 DINAQOR Details
    • 2.4.2 DINAQOR Major Business
    • 2.4.3 DINAQOR Gene Therapy For Heart Failure Product and Solutions
    • 2.4.4 DINAQOR Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 DINAQOR Recent Developments and Future Plans
  • 2.5 PRECIGEN
    • 2.5.1 PRECIGEN Details
    • 2.5.2 PRECIGEN Major Business
    • 2.5.3 PRECIGEN Gene Therapy For Heart Failure Product and Solutions
    • 2.5.4 PRECIGEN Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 PRECIGEN Recent Developments and Future Plans
  • 2.6 Heartseed
    • 2.6.1 Heartseed Details
    • 2.6.2 Heartseed Major Business
    • 2.6.3 Heartseed Gene Therapy For Heart Failure Product and Solutions
    • 2.6.4 Heartseed Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Heartseed Recent Developments and Future Plans
  • 2.7 Cardior
    • 2.7.1 Cardior Details
    • 2.7.2 Cardior Major Business
    • 2.7.3 Cardior Gene Therapy For Heart Failure Product and Solutions
    • 2.7.4 Cardior Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Cardior Recent Developments and Future Plans
  • 2.8 NOVARTIS
    • 2.8.1 NOVARTIS Details
    • 2.8.2 NOVARTIS Major Business
    • 2.8.3 NOVARTIS Gene Therapy For Heart Failure Product and Solutions
    • 2.8.4 NOVARTIS Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 NOVARTIS Recent Developments and Future Plans
  • 2.9 Blue Rock
    • 2.9.1 Blue Rock Details
    • 2.9.2 Blue Rock Major Business
    • 2.9.3 Blue Rock Gene Therapy For Heart Failure Product and Solutions
    • 2.9.4 Blue Rock Gene Therapy For Heart Failure Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Blue Rock Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Gene Therapy For Heart Failure Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Gene Therapy For Heart Failure by Company Revenue
    • 3.2.2 Top 3 Gene Therapy For Heart Failure Players Market Share in 2022
    • 3.2.3 Top 6 Gene Therapy For Heart Failure Players Market Share in 2022
  • 3.3 Gene Therapy For Heart Failure Market: Overall Company Footprint Analysis
    • 3.3.1 Gene Therapy For Heart Failure Market: Region Footprint
    • 3.3.2 Gene Therapy For Heart Failure Market: Company Product Type Footprint
    • 3.3.3 Gene Therapy For Heart Failure Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Gene Therapy For Heart Failure Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Gene Therapy For Heart Failure Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Gene Therapy For Heart Failure Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Gene Therapy For Heart Failure Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Gene Therapy For Heart Failure Consumption Value by Type (2018-2029)
  • 6.2 North America Gene Therapy For Heart Failure Consumption Value by Application (2018-2029)
  • 6.3 North America Gene Therapy For Heart Failure Market Size by Country
    • 6.3.1 North America Gene Therapy For Heart Failure Consumption Value by Country (2018-2029)
    • 6.3.2 United States Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Gene Therapy For Heart Failure Consumption Value by Type (2018-2029)
  • 7.2 Europe Gene Therapy For Heart Failure Consumption Value by Application (2018-2029)
  • 7.3 Europe Gene Therapy For Heart Failure Market Size by Country
    • 7.3.1 Europe Gene Therapy For Heart Failure Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 7.3.3 France Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Gene Therapy For Heart Failure Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Gene Therapy For Heart Failure Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Gene Therapy For Heart Failure Market Size by Region
    • 8.3.1 Asia-Pacific Gene Therapy For Heart Failure Consumption Value by Region (2018-2029)
    • 8.3.2 China Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 8.3.5 India Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Gene Therapy For Heart Failure Consumption Value by Type (2018-2029)
  • 9.2 South America Gene Therapy For Heart Failure Consumption Value by Application (2018-2029)
  • 9.3 South America Gene Therapy For Heart Failure Market Size by Country
    • 9.3.1 South America Gene Therapy For Heart Failure Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Gene Therapy For Heart Failure Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Gene Therapy For Heart Failure Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Gene Therapy For Heart Failure Market Size by Country
    • 10.3.1 Middle East & Africa Gene Therapy For Heart Failure Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Gene Therapy For Heart Failure Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Gene Therapy For Heart Failure Market Drivers
  • 11.2 Gene Therapy For Heart Failure Market Restraints
  • 11.3 Gene Therapy For Heart Failure Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Gene Therapy For Heart Failure Industry Chain
  • 12.2 Gene Therapy For Heart Failure Upstream Analysis
  • 12.3 Gene Therapy For Heart Failure Midstream Analysis
  • 12.4 Gene Therapy For Heart Failure Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Gene therapy provides a novel strategy for targeting abnormalities in heart cells that adversely affect heart function.
    According to our (Global Info Research) latest study, the global Gene Therapy For Heart Failure market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Gene Therapy For Heart Failure market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Gene Therapy For Heart Failure market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Gene Therapy For Heart Failure market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Gene Therapy For Heart Failure market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Gene Therapy For Heart Failure market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gene Therapy For Heart Failure
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gene Therapy For Heart Failure market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Askbio, RENOVACORINC, Uniqure, DINAQOR and PRECIGEN, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Gene Therapy For Heart Failure market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Gene Modification
    Gene Replacement
    Others
    Market segment by Application
    Hospital
    Laboratory
    Others
    Market segment by players, this report covers
    Askbio
    RENOVACORINC
    Uniqure
    DINAQOR
    PRECIGEN
    Heartseed
    Cardior
    NOVARTIS
    Blue Rock
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Gene Therapy For Heart Failure product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Gene Therapy For Heart Failure, with revenue, gross margin and global market share of Gene Therapy For Heart Failure from 2018 to 2023.
    Chapter 3, the Gene Therapy For Heart Failure competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy For Heart Failure market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy For Heart Failure.
    Chapter 13, to describe Gene Therapy For Heart Failure research findings and conclusion.

    Buy now